Skip to main content
. 2022 Apr 30;80:104013. doi: 10.1016/j.ebiom.2022.104013

Figure 5.

Figure 5

B cells, T cells and NK cells following STEMI. Levels of (a) NK cells, (b) B cells (CD19), (c) CD4+ T cells and (d) CD8+ T cells in STEMI patients (only placebo) at hospitalisation (n = 30), 24 h (n = 31), 3-7 days (n = 29) and 6 months (n = 30) compared with stabile angina pectoris (SAP) patients (n = 20). Data are presented as mean with SEM. Grey-shaded area: normal range. *p < 0.05 versus SAP (One-way ANOVA with Dunnett's multiple comparisons test). Data are given as mean and SEM. Hospital admission was within 6 h after symptom onset. Panel e shows significantly DEGs (adjusted p-value < 0.05, average gene expression > 50) in T cells between the treatment groups at hospitalisation (placebo [p]: n = 10, tocilizumab [t]: n = 6), 24 h after hospitalisation (p: n = 8, t: n = 8), after 3-7 days (p: n = 8, t: n = 8) and after 6 months (p: n = 10, t: n = 9).